AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17201457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study 17201457 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-mycophenolate sodium
Number of subjects: 0
Study 17201457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate therapy
Number of subjects: 0
Study 16263350 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular brachytherapy (VBT) during stented angioplasty
Number of subjects: 61
Study 16263350 — intervention group
Group type: COMPARATOR
Intervention: Control group (stent implantation without VBT)
Number of subjects: 61
Study 11934202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine ophthalmic solution 0.5%
Number of subjects: 39
Study 11934202 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Lens Plus)
Number of subjects: 39
Study 10774765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B surface antigen (HbsAg)
Number of subjects: 824
Study 10774765 — intervention group
Group type: COMPARATOR
Intervention: No hepatitis B surface antigen (control)
Number of subjects: 824
Study 8625175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sho-saiko-to (TJ-9) at a daily oral dose of 7.5 g
Number of subjects: 260
Study 8625175 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs (Control)
Number of subjects: 260
Study 31241992 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 77
Study 31241992 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg and 100 mg)
Number of subjects: 77
Study 31241992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 29231322 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture based on nourishing spleen and kidney and dredging the governor vessel, applied for 3 sessions with 20 days at the interval, 10 times as one session, once every other day.
Number of subjects: 120
Study 29231322 — intervention group
Group type: COMPARATOR
Intervention: Control group received physicotherapeutics and hand function training for 3 sessions with 20 days at the interval, 20 times as one session, once a day.
Number of subjects: 120
Study 25491792 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39758979 100 mg
Number of subjects: 88
Study 25491792 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39758979 300 mg
Number of subjects: 88
Study 25491792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25491792 — intervention group
Group type: COMPARATOR
Intervention: JNJ‐39758979 and Placebo
Number of subjects: 88
Study 23941576 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stroke care plus auto-BPAP initiated within 24 hours of stroke onset for a maximum of 48 hours.
Number of subjects: 0
Study 23941576 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke care alone.
Number of subjects: 0
Study 23941576 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stroke care plus auto-BPAP.
Number of subjects: 0
Study 21480979 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg/kg BW)
Number of subjects: 50
Study 21480979 — intervention group
Group type: COMPARATOR
Intervention: Microcrystalline cellulose (Control)
Number of subjects: 50
Study 19535182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track group (FT)
Number of subjects: 105
Study 19535182 — intervention group
Group type: COMPARATOR
Intervention: Non-fast-track group (non-FT)
Number of subjects: 105
Study 16455421 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (n = 26)
Number of subjects: 52
Study 16455421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 52
Study 14692930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air analgesia
Number of subjects: 26
Study 14692930 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy without cold air analgesia
Number of subjects: 26
Study 11533327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 69
Study 11533327 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 69
Study 9578908 — intervention group
Group type: EXPERIMENTAL
Intervention: Random task
Number of subjects: 0
Study 9578908 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal tasks
Number of subjects: 0
Study 9578908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical tasks
Number of subjects: 0
Study 9578908 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional tasks
Number of subjects: 0
Study 7506180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide suspension (1.5 mg/kg 3 times daily)
Number of subjects: 110
Study 7506180 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol syrup (10 mg/kg 4 times daily)
Number of subjects: 110
Study 7506180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 110
Study 7506180 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 110
Study 2882288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg for children under 5, 60 mg for older children)
Number of subjects: 140
Study 2882288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 2882288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 140
Study 31764165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dismissive scenario
Number of subjects: 326
Study 31764165 — intervention group
Group type: COMPARATOR
Intervention: Appropriate scenario
Number of subjects: 326
Study 31241362 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 1512
Study 31241362 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 1512
Study 28472976 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (25 mg three times a day for 8 weeks)
Number of subjects: 103
Study 28472976 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (in vitro)
Number of subjects: 103
Study 28472976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DHEA supplementation)
Number of subjects: 103
Study 28472976 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA group (with ≥5 oocytes retrieved)
Number of subjects: 103
Study 25595984 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance imaging (rtfMRI) training
Number of subjects: 0
Study 25595984 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23798587 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control depletion (experimental condition)
Number of subjects: 62
Study 23798587 — intervention group
Group type: COMPARATOR
Intervention: Nondepletion (control condition)
Number of subjects: 62
Study 20228689 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 477
Study 20228689 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids
Number of subjects: 477
Study 19504088 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of reaching using a non-robotic upper limb training device, the SMART Arm, with EMG triggered functional electrical stimulation (EMG-stim)
Number of subjects: 42
Study 19504088 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of reaching using the SMART Arm alone
Number of subjects: 42
Study 19504088 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 42
Study 16430794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg administered perioperatively
Number of subjects: 540
Study 16430794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg administered only postoperatively
Number of subjects: 540
Study 16430794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 12928319 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative-group testing (group A)
Number of subjects: 38
Study 12928319 — intervention group
Group type: COMPARATOR
Intervention: Traditional individual testing (group B)
Number of subjects: 38
Study 10638466 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) for 10 days preoperatively and 9 days postoperatively
Number of subjects: 90
Study 10638466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative nutrition, 940 kcal nonprotein plus 85 g amino acids postoperatively)
Number of subjects: 90
Study 10638466 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 90
Study 10638466 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 9375889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day of liquid folic acid
Number of subjects: 19
Study 9375889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1608268 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methanolic leaf extract cream of Solanum chrysotrichum
Number of subjects: 200
Study 1608268 — intervention group
Group type: COMPARATOR
Intervention: Miconazole treatment (control group)
Number of subjects: 200
Study 1608268 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methanolic leaf extract
Number of subjects: 200
Study 3929513 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing factor (GRF) 100 micrograms
Number of subjects: 32
Study 3929513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diluent only)
Number of subjects: 32
Study 3929513 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 32
Study 29451355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin 2S
Number of subjects: 0
Study 29451355 — intervention group
Group type: COMPARATOR
Intervention: In vitro model
Number of subjects: 0
Study 28094169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU twice daily)
Number of subjects: 68
Study 28094169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 25763921 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training 3 times a week for 6 months in addition to standard pulmonary rehabilitation (PR)
Number of subjects: 0
Study 25763921 — intervention group
Group type: COMPARATOR
Intervention: Standard pulmonary rehabilitation (PR) only
Number of subjects: 0
Study 23736807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 50
Study 23736807 — intervention group
Group type: COMPARATOR
Intervention: Standard RV-PGR (comparator)
Number of subjects: 50
Study 21493740 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (ICO) - treated with 1.5 or 2.0 L of 7.5% icodextrin‐containing solutions
Number of subjects: 41
Study 21493740 — intervention group
Group type: COMPARATOR
Intervention: Glucose (GLU) - treated with 8 L of 1.5% or 2.5% glucose
Number of subjects: 41
Study 21493740 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (ICO)
Number of subjects: 41
Study 21493740 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (ICO) and Glucose (GLU)
Number of subjects: 41
Study 18652267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic Primer/LinkmaxHV (CP/LMHV) with 37% phosphoric acid treatment (PA)
Number of subjects: 0
Study 18652267 — intervention group
Group type: EXPERIMENTAL
Intervention: Monobond S/VariolinkIIHV (MBS/VLIIHV) with 37% phosphoric acid treatment (PA)
Number of subjects: 0
Study 18652267 — intervention group
Group type: EXPERIMENTAL
Intervention: MBS/HB/VLIIHV with various surface treatments
Number of subjects: 0
Study 18652267 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina blasting with each of three RBSs
Number of subjects: 0
Study 18652267 — intervention group
Group type: EXPERIMENTAL
Intervention: All combined groups of ceramic surface treatment and resin bonding system
Number of subjects: 0
Study 16395725 — intervention group
Group type: EXPERIMENTAL
Intervention: COBE Spectra version 6
Number of subjects: 60
Study 16395725 — intervention group
Group type: COMPARATOR
Intervention: Haemonetics MCS(+)
Number of subjects: 60
Study 15202989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 30
Study 11564035 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeats in the AR gene
Number of subjects: 149
Study 11564035 — intervention group
Group type: EXPERIMENTAL
Intervention: TA repeats in the ER gene
Number of subjects: 149
Study 10023258 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser at 0.50 W
Number of subjects: 60
Study 10023258 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser at 0.75 W
Number of subjects: 60
Study 10023258 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser at 1.00 W
Number of subjects: 60
Study 10023258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber sizes of 140, 245, 355, and 410 microns
Number of subjects: 60
Study 10023258 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fiber after lasing
Number of subjects: 60
Study 10023258 — intervention group
Group type: COMPARATOR
Intervention: All power settings
Number of subjects: 60
Study 7817797 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic calcium stone formers (ICSF)
Number of subjects: 110
Study 7817797 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 110
Study 7817797 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic calcium stone formers (ICSF) with low-calcium diet
Number of subjects: 110
Study 7817797 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic calcium stone formers (ICSF) with skeletal score 4
Number of subjects: 110
Study 2648143 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard course of methotrexate for 102 days after transplantation (Group I)
Number of subjects: 109
Study 2648143 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated (11-day) course of methotrexate (Group II)
Number of subjects: 109
Study 2648143 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard course of methotrexate plus viable buffy-coat cells from marrow donors (Group III)
Number of subjects: 109
Study 31931852 — intervention group
Group type: EXPERIMENTAL
Intervention: New recruitment approach with continuous information and gratification (Swiss chocolate and free soft drinks)
Number of subjects: 0
Study 29889285 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine in combination therapy (HD-ECM)
Number of subjects: 0
Study 29889285 — intervention group
Group type: COMPARATOR
Intervention: Standard combination therapy (ECM)
Number of subjects: 0
Study 27321554 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% testosterone propionate (TG)
Number of subjects: 69
Study 27321554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% estradiol (EG)
Number of subjects: 69
Study 27321554 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (CG)
Number of subjects: 69
Study 25263372 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine (group A)
Number of subjects: 90
Study 25263372 — intervention group
Group type: COMPARATOR
Intervention: Urapidil (group B)
Number of subjects: 90
Study 25263372 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil combined with phentolamine (group C)
Number of subjects: 90
Study 24045740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care management (CCM), n=282
Number of subjects: 563
Study 24045740 — intervention group
Group type: COMPARATOR
Intervention: No CCM (control), n=281
Number of subjects: 563
Study 24045740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care management (CCM) for alcohol dependence
Number of subjects: 563
Study 21358207 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (30 mg/m² on days 1, 8, and 15; q4w)
Number of subjects: 162
Study 21358207 — intervention group
Group type: COMPARATOR
Intervention: Standard docetaxel (75 mg/m² every 3 weeks; q3w)
Number of subjects: 162
Study 19274909 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 99
Study 19274909 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no MBP)
Number of subjects: 99
Study 16616726 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 16616726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16616726 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine hormone responses
Number of subjects: 0
Study 12682721 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (1 micro g.kg.24 h) for 10 days as a continuous infusion
Number of subjects: 27
Study 12682721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 11056751 — intervention group
Group type: EXPERIMENTAL
Intervention: 50%/50% heliox
Number of subjects: 10
Study 11056751 — intervention group
Group type: EXPERIMENTAL
Intervention: 60%/40% heliox
Number of subjects: 10
Study 11056751 — intervention group
Group type: EXPERIMENTAL
Intervention: 70%/30% heliox
Number of subjects: 10
Study 11056751 — intervention group
Group type: COMPARATOR
Intervention: 50%/50% nitrogen/oxygen
Number of subjects: 10
Study 8623958 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) evaluation by three independent, blinded observers
Number of subjects: 40
Study 1729857 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 127
Study 1729857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 6738337 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of 10 mg/kg metrifonate
Number of subjects: 286
Study 6738337 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 10 mg/kg metrifonate
Number of subjects: 286
Study 6738337 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 10 mg/kg metrifonate
Number of subjects: 286
Study 30761523 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril (100 mg) - acute administration
Number of subjects: 21
Study 30761523 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril (100 mg; t.i.d.) - chronic administration for 14 days
Number of subjects: 21
Study 30761523 — intervention group
Group type: COMPARATOR
Intervention: Placebo - acute administration
Number of subjects: 21
Study 30761523 — intervention group
Group type: COMPARATOR
Intervention: Placebo - chronic administration for 14 days
Number of subjects: 21
Study 30336290 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL-PDT)
Number of subjects: 60
Study 30336290 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (C-PDT)
Number of subjects: 60
Study 27115126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) 200 g daily during the first 3 months of ART
Number of subjects: 282
Study 27115126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 282
Study 27115126 — intervention group
Group type: COMPARATOR
Intervention: Control group (ART without LNS)
Number of subjects: 282
Study 24961851 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of DEHP estimated using the urine volume (UV) model
Number of subjects: 129
Study 24961851 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of DEHP estimated using the urine creatinine-excretion (UCE) model
Number of subjects: 129
Study 24961851 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (administrators)
Number of subjects: 129
Study 24961851 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (laboratory technicians)
Number of subjects: 129
Study 23264537 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized model (6.4 h/wk; 80% low, 0% moderate, 20% high intensity)
Number of subjects: 12
Study 23264537 — intervention group
Group type: COMPARATOR
Intervention: Threshold model (7.5 h/wk; 57% low, 43% moderate, 0% high intensity)
Number of subjects: 12
Study 23264537 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized model
Number of subjects: 12
Study 23264537 — intervention group
Group type: COMPARATOR
Intervention: Threshold model
Number of subjects: 12
Study 20059413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg and Amoxicillin 375 mg, three times a day for 7 days
Number of subjects: 51
Study 20059413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 20059413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Amoxicillin
Number of subjects: 51
Study 19035876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily for 4 weeks)
Number of subjects: 76
Study 19035876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 19035876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 76
Study 15844840 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal herb tea (MHT)
Number of subjects: 100
Study 15844840 — intervention group
Group type: COMPARATOR
Intervention: Non-MHT taking subjects (Control)
Number of subjects: 100
Study 14765605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation procedures involving verbal descriptions of the correct response
Number of subjects: 40
Study 14765605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation procedures requiring explicit reading of verbal descriptions
Number of subjects: 40
Study 14765605 — intervention group
Group type: COMPARATOR
Intervention: Training control procedures (for 8 subjects)
Number of subjects: 40
Study 10225812 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral gold salt therapy
Number of subjects: 128
Study 10225812 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral gold salt therapy (withdrawn due to side effects)
Number of subjects: 128
Study 10225812 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (withdrawn due to side effects)
Number of subjects: 128
Study 8876346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (GS) 8 or 16 mg/kg body weight daily for 7 days
Number of subjects: 0
Study 8876346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 8876346 — intervention group
Group type: COMPARATOR
Intervention: Control (CN)
Number of subjects: 0
Study 1984328 — intervention group
Group type: EXPERIMENTAL
Intervention: TE of 12 msec
Number of subjects: 28